CAS: 99300-78-4; Venlafaxine Hydrochloride

上下游产品

CAS号50-00-0 甲醛 | CAS号93413-69-5 D,L-文拉法辛 | CAS号93413-77-5 1-[2-氨基-1-(4-甲氧... | CAS号130198-05-9 1-[2-氨基-1-(4-甲氧... | CAS号64-18-6 甲酸 | CAS号93413-76-4 1-羟基环己基-4-甲氧基苯乙腈 | CAS号108-94-1 环己酮 | CAS号104-47-2 对甲氧基苯乙腈 | CAS号93413-62-8 O-去甲文拉法辛 | CAS号93413-69-5 D,L-文拉法辛 | CAS号448904-47-0 WY 45233 succinate

1-[2-氨基-1-(4-甲氧基苯基)乙基]环己醇置于聚合甲醛,甲酸,盐酸体系中,用 水,甲苯,丙酮 作为反应溶剂,化学反应 10.0H,以90%的收率获得产物盐酸文拉法辛
参考文献:一种盐酸文拉法辛中间体的合成方法
标题:一种盐酸文拉法辛中间体的合成方法
摘要:本发明提供一种盐酸文拉法辛中间体的合成方法,盐酸文拉法辛中间体为式ⅰ化合物1‑[2‑氨基‑1‑(4‑甲氧基苯基)乙基]环己醇,本发明以式ⅱ化合物1‑氰基‑(4‑甲氧基苯基)甲基环己醇为原料进行氢化催化反应,采用铜‑镍催化剂进行氢化催化反应得到上述式ⅰ化合物.使用该方法生产的盐酸文拉法辛可以有效控制杂质的产生,提高式ⅰ化合物的产率和纯度.

专利信息

专利号:US-9527800-B2
优先权日:2013-10-29
标 题:Process for total synthesis of venlafaxine
发明人：CHAVAN SUBHASH PRATAPRAO; PAWAR KAILASH PRALHAD
权利人:COUNCIL SCIENT IND RES
摘要:There is a need for short, resolution free asymmetric process for synthesis of one isomer of venlafaxine, (−)-venlafaxine. The invention provides a novel, short process of synthesis of (−)-venlafaxine, with yield greater than 50% and ee>99%. This process can be used for racemic synthesis of venlafaxine with overall yield 65%.

专利号:US-7612210-B2
优先权日:2005-12-05
标题:Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
发明人：MAHANEY PAIGE ERIN; ANTANE MADELENE MIYOKO; SUN JERRY SHUNNENG
权利人:WYETH CORP
摘要:A process for the enantioselective synthesis of an (S)- or (R)-1-[2-dimethylamino)-1-(methoxyphenyl)ethyl]cyclohexanol and analogues or salt thereof are described. The method involves the steps of (a) reacting an (S) or (R) 4-benzyloxazolidinone with a mixed anhydride of a methyoxyphenylacetic acid under conditions which form a oxazolidinone, (4S)- or (4R)-4-benzyl-3-[methyoxyphenyl]acetyl]-oxazolidin-2-one, (b) treating the (4S)- or (4R)-4-benzyl-3-[(methoxyphenyl)acetyl]-1,3-oxazolidin-2-one with an aprotic amine base and titanium chloride in a chlorinated solvent under conditions which permit formation of the corresponding anion, (c) mixing the corresponding anion with titanium chloride and cylcohexanone under conditions which permit an aldol reaction to form the corresponding (4S)- or (4R)-4-benzyl-3-[(2R)-2-(1-hydroxycyclohexyl)-2-(methoxyphenyl)acetyl]-1,3-oxazolidin-2-one,(d) hydrolyzing the (4S)— or (4R)-4-benzyl-3-[(2R)-2-(1-hydroxycyclohexyl)-2-(methoxyphenyl)acetyl]-1,3-oxazolidin-2-one to form a chiral acid (2S or 2R)-(1-hydroxycyclohexyl)-methoxyphenyl)acetic acid, (e) coupling the chiral phenylacid to a secondary amine to form an amide, and (f) reducing the amide to form an (S) or (R) 1[2-dimethylamino)-1-(methoxyphenyl)ethyl]cyclohexanol or a salt thereof.

专利号:US-2003083352-A1
优先权日:2000-07-31
标 题 :Synthesis of imidazole intermediates
发明人：HELAL CHRISTOPHER J
权利人:PFIZER
摘要:The invention provides a method for synthesis of compounds of formula n n n wherein R 1 and R 19 are as defined. Compounds of formula 12 are useful as intermediates for synthesizing compounds having pharmacological activity inhibiting cdk5, cdk2, and GSK-3.

专利号:US-2006030625-A1
优先权日:2004-08-06
标 题 :Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
发明人：HART CHERYLE RAM; GROSSMAN RONALD S; RAM HERBERT
权利人:HART CHERYLE RAM; GROSSMAN RONALD S; RAM HERBERT
摘要:Dietary supplements for treating a neurotransmitter deficiency include one or more precursors of the deficient neurotransmitter and a cofactor for activating in vivo enzymatic synthesis of the deficient neurotransmitter. The dietary supplements can also include an appropriate neurotransmitter, such as an amino acid. When administered through the oral mucosa, increases in levels of the deficient neurotransmitters and relief from deficiency symptoms are obtained.

专利号:US-8569265-B2
优先权日:2011-05-06
标题:Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3′, 4′:6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof
发明人：CHEN XINGHAI; HUANG QIULI; KOCHAT HARRY; MALAKHOV ANDREY; HAUSHEER FREDERICK H
权利人:CHEN XINGHAI; HUANG QIULI; KOCHAT HARRY; MALAKHOV ANDREY; HAUSHEER FREDERICK H; BIONUMERIK PHARMACEUTICALS INC
摘要:The present invention discloses: (i) two novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof.

专利号:US-12295961-B2
优先权日:2009-12-31
标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
发明人：DHINGRA OM
权利人:MARIUS PHARMACEUTICALS INC
摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.